Cartesian Therapeutics, Inc. (RNAC) Net margin 2016–2025
Cartesian Therapeutics, Inc. (RNAC) net profit margin by fiscal year — reported net income divided by reported revenue.
-32575.5%FY2025 · since FY2016: -448.0% → -32575.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -32575.5% | -32373.2 pp |
| FY2024 | -202.3% | +642.6 pp |
| FY2023 | -844.9% | -876.8 pp |
| FY2022 | 31.9% | +62.1 pp |
| FY2021 | -30.2% | +384.8 pp |
| FY2020 | -415.0% | +414.0 pp |
| FY2019 | -829.0% | +6406.5 pp |
| FY2018 | -7235.4% | +24320.6 pp |
| FY2017 | -31556.0% | -31108.1 pp |
| FY2016 | -448.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice